| Title: |
COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil. |
| Authors: |
Randi, Bruno Azevedo, Higashino, Hermes Ryoiti, Ponzio da Silva, Vinícius, Salomão, Matias Chiarastelli, Campos Pignatari, Antonio Carlos, Abdala, Edson, Vasques, Fabiana, Rodrigues da Silva, Celso Arrais, Luiz da Silva, Roberto, dos Santos Lazari, Carolina, Levi, José Eduardo, Xavier, Erick Menezes, Côrtes, Marina Farrel, Luna-Muschi, Alessandra, Rocha, Vanderson, Costa, Silvia Figueiredo |
| Source: |
Revista do Instituto de Medicina Tropical de São Paulo; 2024, Vol. 66, p1-7, 7p |
| Subject Terms: |
STEM cell transplantation, HEMATOPOIETIC stem cells, MULTIPLE regression analysis, INFECTION prevention, COMPUTED tomography |
| Abstract: |
Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in two large hospitals in São Paulo, Brazil post-HSCT, from January 2020 to June 2022. The primary outcome was all-cause mortality. Of 49 cases, 63.2% were male with a median age of 47 years. Allogeneic-HSCT (51.2%) and autologous-HSCT (48.9%) patients were included. The median time from HSCT to COVID-19 diagnosis was 398 days (IQR: 1211-134), with 22 (44.8%) cases occurring within 12 months of transplantation. Most cases occurred during the first year of the pandemic, in non-vaccinated patients (n=35; 71.4%). Most patients developed severe (24.4%) or critical (40.8%) disease; 67.3% received some medication for COVID-19, primarily corticosteroids (53.0%). The probable invasive aspergillosis prevalence was 10.2%. All-cause mortality was 40.8%, 51.4% in non-vaccinated patients and 14.2% in patients who received at least one dose of the vaccine. In the multiple regression analyses, the variables mechanical ventilation (OR: 101.01; 95% CI: 8.205 - 1,242.93; p = 0.003) and chest CT involvement at diagnosis =50% (OR: 26.61; 95% CI: 1.06 - 664.26; p = 0.04) remained associated with all-cause mortality. Thus, HSCT recipients with COVID-19 experienced high mortality, highlighting the need for full vaccination and infection prevention measures. [ABSTRACT FROM AUTHOR] |
|
Copyright of Revista do Instituto de Medicina Tropical de São Paulo is the property of Instituto de Medicina Tropical de Sao Paulo and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
